anti-cdh17/exatecan antibody-drug conjugate arr-217
Generic: Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217
anti-cdh17/exatecan antibody-drug conjugate arr-217: 1 clinical trial tracked.
anti-cdh17/exatecan antibody-drug conjugate arr-217 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-cdh17/exatecan antibody-drug conjugate arr-217, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Primary endpoint: Dose Limiting Toxicity (DLT) - Phase Ia
Interventionalopen572 targetStarted 2025-07Completion 2030-1221 sites · China, United StatesArriVent BioPharma, Inc.